BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, Xu RH. Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. World J Gastroenterol 2010; 16(46): 5881-5888 [PMID: 21155011 DOI: 10.3748/wjg.v16.i46.5881]
URL: https://www.wjgnet.com/1007-9327/full/v16/i46/5881.htm
Number Citing Articles
Brigette B Ma, Frankie Mo, Joanna H Tong, Ashley Wong, SC Cesar Wong, Wing M Ho, Cherry Wu, Polly WY Lam, KF Chan, Timothy SK Chan, Wilson MS Tsui, Alex KH Tsang, Mandy NS Fung, Anthony TC Chan, Ka Fai To. Elucidating the prognostic significance ofKRAS,NRAS,BRAFandPIK3CAmutations in Chinese patients with metastatic colorectal cancerAsia-Pacific Journal of Clinical Oncology 2015; 11(2): 160 doi: 10.1111/ajco.12342
Precision Oncology—The Quest for EvidenceJournal of Personalized Medicine 2019; 9(3): 43 doi: 10.3390/jpm9030043
B.A. Bohn, S. Mina, A. Krohn, R. Simon, M. Kluth, S. Harasimowicz, A. Quaas, M. Bockhorn, J.R. Izbicki, G. Sauter, A. Marx, P.R. Stahl. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancerHuman Pathology 2013; 44(8): 1524 doi: 10.1016/j.humpath.2012.12.006
LEE CHENG PHUA, HUI WEN NG, ANGIE HUI LING YEO, ELYA CHEN, MICHELLE SHU MEI LO, PEH YEAN CHEAH, ERIC CHUN YONG CHAN, POH KOON KOH, HAN KIAT HO. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancerOncology Letters 2015; 10(4): 2519 doi: 10.3892/ol.2015.3560
Zain A Sobani, Ashwin Sawant, Mikram Jafri, Amit Keith Correa, Ibrahim Halil Sahin. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancerWorld Journal of Clinical Oncology 2016; 7(5): 340-351 doi: 10.5306/wjco.v7.i5.340
Amartej Merla, Sanjay Goel. Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic ReviewChemotherapy Research and Practice 2012; 2012: 1 doi: 10.1155/2012/387172
Jing Gao, Ting-ting Wang, Jing-wei Yu, Yan-yan Li, Lin Shen. Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patientsChinese Journal of Cancer Research 2011; 23(4): 271 doi: 10.1007/s11670-011-0271-4
Zhen-Hua Wang, Qin-Yan Gao, Jing-Yuan Fang. Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studiesCancer Chemotherapy and Pharmacology 2012; 69(6): 1647 doi: 10.1007/s00280-012-1886-y
Jihye Yun, George Poulogiannis, Evan T. Brower, Samuel Klempner, Lewis L. Cantley. Molecular Pathogenesis of Colorectal Cancer2013; : 157 doi: 10.1007/978-1-4614-8412-7_6
Christopher Hocking, Jennifer E Hardingham, Vy Broadbridge, Joe Wrin, Amanda R Townsend, Niall Tebbutt, John Cooper, Andrew Ruszkiewicz, Chee Lee, Timothy J Price. Can we accurately report PTEN status in advanced colorectal cancer?BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-128
Gang Wu, Weiyuan Huang, Junnv Xu, Wenzhu Li, Yu Wu, Qianyu Yang, Kun Liu, Mingyue Zhu, Priya S. Balasubramanian, Mengsen Li. Dynamic contrast-enhanced MRI predicts PTEN protein expression which can function as a prognostic measure of progression-free survival in NPC patientsJournal of Cancer Research and Clinical Oncology 2021;  doi: 10.1007/s00432-021-03764-7
Riccardo Giampieri, Mario Scartozzi, Michela Del Prete, Elena Maccaroni, Alessandro Bittoni, Luca Faloppi, Maristella Bianconi, Luca Cecchini, Stefano Cascinu. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovationCritical Reviews in Oncology/Hematology 2013; 88(2): 272 doi: 10.1016/j.critrevonc.2013.05.008
Alexander Picker, David B Jackson. Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicineExpert Review of Molecular Diagnostics 2011; 11(6): 567 doi: 10.1586/erm.11.45
Geraldine Perkins, Camilla Pilati, Helene Blons, Pierre Laurent-Puig. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancerPharmacogenomics 2014; 15(7): 1043 doi: 10.2217/pgs.14.66
Bingjun Bai, Lina Shan, Binbin Xie, Xuefeng Huang, Weifang Mao, Xiaowei Wang, Da Wang, Hongbo Zhu. Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancerOncology Letters 2017;  doi: 10.3892/ol.2017.7709